API Abacavir sulfate

Abacavir sulfate More Info

Abacavir sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 months and older. It is always administered as part of a combination antiretroviral therapy (cART) regimen to suppress viral load, preserve immune function, and slow the progression of HIV disease. A carbocyclic nucleoside analogue, it features high water solubility and has a well-established clinical application profile worldwide.

Key Properties & Formulation

Chemical Identity: (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (2:1 salt). Its molecular formula is (C₁₄H₁₈N₆O)₂·H₂SO₄, with a molecular weight of approximately 670.76 Da. It appears as a white to off-white solid, and its water solubility reaches about 77 mg/mL at 25°C.

Dosage Forms: Available as oral tablets (containing 300 mg abacavir equivalent) and oral solution (20 mg/mL abacavir equivalent). It can be taken once or twice daily, with or without food.

Mechanism of Action

After oral administration, abacavir is phosphorylated intracellularly into its active metabolite, carbovir triphosphate (CBV-TP). This metabolite competes with natural guanosine triphosphate (dGTP) for incorporation into the viral complementary DNA (cDNA) chain synthesized by HIV reverse transcriptase. Once incorporated, it terminates the elongation of the viral cDNA chain, thereby blocking viral replication and reducing the production of infectious viral particles.

Clinical Use & Dosing

Adults and Adolescents: The typical dosage is 600 mg once daily, or 300 mg twice daily, as a component of cART.

Pediatric Patients: Dosing is weight-based, for example, 8 mg/kg twice daily (maximum 300 mg per dose). Oral solution or scored tablets can be used, and dosage adjustments are required for patients with renal or hepatic impairment.

Fixed-Dose Combinations (FDCs): Abacavir is often co-formulated with other antiretroviral drugs such as lamivudine and/or dolutegravir. This formulation simplifies medication adherence and improves the tolerability of the treatment regimen.

Safety Profile & Warnings

Hypersensitivity Reaction (HSR): This is a life-threatening, multi-organ reaction characterized by symptoms such as rash, fever, nausea, vomiting, dyspnea, and hypotension. It is strongly associated with the HLA-B5701 genetic allele. Mandatory pre-screening for the HLA-B5701 allele is required before initiating treatment. If a hypersensitivity reaction is suspected, abacavir sulfate must be discontinued immediately, and re-administration is strictly prohibited.

Common Adverse Effects: Mild to moderate symptoms including nausea, headache, fatigue, diarrhea, and insomnia are common. These symptoms usually resolve spontaneously over time.

Serious Risks: Rare but severe adverse events include lactic acidosis accompanied by hepatomegaly, immune reconstitution inflammatory syndrome (IRIS) in patients with advanced HIV infection, and potential cardiovascular events. Patients with relevant risk factors need close monitoring.

Pregnancy and Lactation: The drug should be used only when the potential benefits outweigh the risks. Breastfeeding is not recommended for HIV-positive patients to avoid mother-to-child transmission of the virus.

Pharmacokinetics & Drug Interactions

Pharmacokinetics: Abacavir sulfate is rapidly absorbed after oral administration, with high bioavailability. Its elimination half-life is approximately 1.5 hours, and no significant accumulation occurs with long-term administration. It is mainly metabolized in the liver via alcohol dehydrogenase and glucuronidation pathways. Approximately 83% of the metabolites are excreted in urine, and 17% in feces; only about 2% of the unchanged drug is excreted via the kidneys.

Drug Interactions: It has a low potential for interactions mediated by the cytochrome P450 (CYP450) enzyme system. Co-administration with alcohol should be avoided, as it may increase the risk of liver injury. When used with other myelosuppressive drugs (e.g., zidovudine), close monitoring is required to detect additive myelosuppressive effects.

Resistance & Monitoring

Resistance Development: Viral resistance can occur if the drug is used as monotherapy or if the patient has suboptimal adherence to the treatment regimen. Common resistance-related mutations include K65R, L74V, and M184V.

Clinical Monitoring: During treatment, regular monitoring of viral load, CD4+ T-cell count, liver and renal function, and blood lipid levels is recommended to evaluate treatment efficacy and detect potential adverse reactions in a timely manner.